TG Therapeutics (TGTX) Financial Analysis & Valuation | Quarter Chart

TG Therapeutics (TGTX)

TGTX
Price: $55.72
Fair Value: 🔒
🔒score
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclon... more
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, dev... more
Description Shares
Market Cap$8.53BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOMichael S. Weiss
IPO Date2010-05-03CAGR0.35%
Employees352Websitewww.tgtherapeutics.com
Div. Yield—Payout Ratio—
Buy Back Yield0.72%Total Yield0.72%
TGTX chart loading...
Fundamentals Technicals
Enterprise Value$6.19BP/E Ratio19.15
Forward P/E19.4PEG Ratio0.06
P/S Ratio16.87P/B Ratio18.33
P/CF Ratio-765.89P/FCF Ratio-832.43
EPS$2.91EPS Growth 1Y1070.69%
EPS Growth 3Y-332.52%EPS Growth 5Y-210%
Revenue Growth 1Y81.26%Gross Margin0.83%
Operating Margin0.21%Profit Margin0.66%
ROE0.87%ROA0.3%
ROCE0.11%Current Ratio5.81
Quick Ratio5.12Cash Ratio2.36
Debt/Equity0.01Interest Coverage5.41
Altman Z Score5.94Piotroski Score5

View TG Therapeutics financial charts →